Alvotech expands its board of directors as part of transition from private to publicly traded company

Alvotech (nasdaq and first north growth market: alvo), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, today announced the expansion of its board of directors as part of its transition from a private to a publicly traded company. the four incoming board members, lisa graver, arni hardarson, linda mcgoldrick and ann merchant joined robert wessman, founder and executive chairman, richard davies, tomas ekman and faysal kalmoua. ms. merchant, ms. mcgoldrick, and mr. davies serve as independent directors of the board.
ALVO Ratings Summary
ALVO Quant Ranking